Items where authors include "Crowley, R.K."

Article

Kamenicky, P. orcid.org/0000-0002-1994-4226, Briot, K. orcid.org/0000-0002-6238-2601, Brandi, M.L. orcid.org/0000-0002-8741-0592 et al. (14 more authors) (2023) Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open, 9 (1). e002676. ISSN 2056-5933

Abbas, A., Schini, M. orcid.org/0000-0003-2204-2095, Ainsworth, G. et al. (7 more authors) (2022) Effect of AZD4017, a selective 11β-HSD1 inhibitor, on bone turnover markers in postmenopausal osteopenia. Journal of Clinical Endocrinology and Metabolism, 107 (7). pp. 2026-2035. ISSN 0021-972X

Briot, K., Portale, A.A., Brandi, M.L. et al. (27 more authors) (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open, 7 (3). e001714. ISSN 2056-5933

Cronin, O. orcid.org/0000-0002-1365-9942, Forsyth, L., Goodman, K. et al. (39 more authors) (2019) Zoledronate in the prevention of Paget's (ZiPP) : protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone. BMJ Open, 9 (9). e030689.